Investigational Drug Information for SM04690
✉ Email this page to a colleague
What is the drug development status for SM04690?
SM04690 is an investigational drug.
There have been 12 clinical trials for SM04690.
The most recent clinical trial was a Phase 3 trial, which was initiated on May 26th 2020.
The most common disease conditions in clinical trials are Osteoarthritis, Osteoarthritis, Knee, and Spinal Diseases. The leading clinical trial sponsors are Biosplice Therapeutics, Inc., Samumed LLC, and [disabled in preview].
There are ten US patents protecting this investigational drug and ninety-nine international patents.
Summary for SM04690
| US Patents | 10 |
| International Patents | 99 |
| US Patent Applications | 38 |
| WIPO Patent Applications | 12 |
| Japanese Patent Applications | 5 |
| Clinical Trial Progress | Phase 3 (2020-05-26) |
| Vendors | 30 |
Recent Clinical Trials for SM04690
| Title | Sponsor | Phase |
|---|---|---|
| A Study Utilizing Patient-Reported Outcomes to Evaluate the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis (STRIDES) | Biosplice Therapeutics, Inc. | Phase 3 |
| 3-year, Open-Label Study Evaluating Safety, Tolerability, and Efficacy of Lorecivivint in Subjects With Osteoarthritis of the Knee | Biosplice Therapeutics, Inc. | Phase 3 |
| Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy Volunteers | Biosplice Therapeutics, Inc. | Phase 1 |
Clinical Trial Summary for SM04690
Top disease conditions for SM04690
Top clinical trial sponsors for SM04690
US Patents for SM04690
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| SM04690 | ⤷ Try a Trial | Process for preparing N-(5-(3-(7-(3-fluorophenyl)-3H-imidazo [4,5-C]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide | Samumed, LLC (San Diego, CA) | ⤷ Try a Trial |
| SM04690 | ⤷ Try a Trial | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | Samumed, LLC (San Diego, CA) | ⤷ Try a Trial |
| SM04690 | ⤷ Try a Trial | Treatment of osteoarthritis | Samumed, LLC (San Diego, CA) | ⤷ Try a Trial |
| SM04690 | ⤷ Try a Trial | Process for preparing N-(5-(3-(7-(3-fluorophenyl)-3H-imidazo[4,5-C]pyridin-2-yl)-1H-indazol-5-y- l)pyridin-3-yl)-3-methylbutanamide | Samumed, LLC (San Diego, CA) | ⤷ Try a Trial |
| SM04690 | ⤷ Try a Trial | Single-dose, ready-to-use injectable formulations | Samumed, LLC (San Diego, CA) | ⤷ Try a Trial |
| SM04690 | ⤷ Try a Trial | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | Samumed, LLC (San Diego, CA) | ⤷ Try a Trial |
| SM04690 | ⤷ Try a Trial | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | Samumed, LLC (San Diego, CA) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for SM04690
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| SM04690 | Australia | AU2017274350 | 2036-06-01 | ⤷ Try a Trial |
| SM04690 | Brazil | BR112018074725 | 2036-06-01 | ⤷ Try a Trial |
| SM04690 | Canada | CA3026076 | 2036-06-01 | ⤷ Try a Trial |
| SM04690 | Chile | CL2018003423 | 2036-06-01 | ⤷ Try a Trial |
| SM04690 | Chile | CL2021000611 | 2036-06-01 | ⤷ Try a Trial |
| SM04690 | China | CN109476660 | 2036-06-01 | ⤷ Try a Trial |
| SM04690 | Denmark | DK3464285 | 2036-06-01 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
